Institut Català de la Salut
[Dominguez-Mozo MI] Grupo de Investigacion de Factores ambientales en enfermedades degenerativas, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Red de Enfermedades Inflamatorias (REI), Red Española de Esclerosis Múltiple, Madrid, Spain. [López-Mecández D] Department of Clinical Analysis, Hospital Clínico San Carlos, Instituto de Medicina del Laboratorio (IML), Madrid, Spain. [Villar LM, Villarrubia N] Servicio de Inmunología, Hospital Universitario Ramon y Cajal, Red de Enfermedades Inflamatorias (REI), Red Española de Esclerosis Múltiple, Madrid, Spain. [Costa-Frossard L] Servicio de Neurología, Hospital Universitario Ramon y Cajal, Red de Enfermedades Inflamatorias (REI), Red Española de Esclerosis Múltiple, Madrid, Spain. [Aladro Y] Servicio de Neurología, Hospital Universitario de Getafe, Spain. [Montalbán X, Comabella M] Servei de Neurologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-04-02T12:07:50Z
2025-04-02T12:07:50Z
2025-03
Short-chain fatty acids; Multiple sclerosis; Disability
Ácidos grasos de cadena corta; Esclerosis múltiple; Discapacidad
Àcids grassos de cadena curta; Esclerosi múltiple; Discapacitat
Objective An alteration in the composition of the intestinal microbiota has been observed in patients with multiple sclerosis (pwMS) with respect to healthy controls (HC). Microorganism-derived metabolites such as short-chain fatty acids (SCFA) have been suggested to play a role in the disease. Thus, to analyze the association of SCFA with clinical and radiological parameters of the disease and with those related to the inflammatory response of the immune system. Methods Multicentric observational retrospective cross-sectional study. In addition 161 pwMS and 130 HC were included. The following plasma SCFA were analyzed using liquid chromatography coupled to mass spectrometry: acetate (AA), propionate (PA) and butyrate (BA). Blood cell subpopulations and cytokine expression were analyzed by flow cytometry. Results Plasma PA and PA/AA ratio was lower in pwMS than in HC (P = 0.0001, and P = 0.00005, respectively). PA/AA and BA/AA ratios were lower in pwMS with higher disability (P = 0.001, and P = 0.001, respectively). T2 lesion load inversely correlated with PA/AA (r = −0.353; P = 0.002) and BA/AA (r = −0.322; P = 0.005) ratios. Plasma PA/AA and/or BA/AA ratios negatively correlated with the following pro-inflammatory cytokines producing cells: GM-CSF+CD4+T, GM-CSF+CD8+T, TNF-alpha+CD4+T, TNF-alpha+CD8+T, IFN-gamma+CD4+T, IFN-gamma+CD8+T, and TNF-alpha+B cells. Interpretation In MS, plasma PA/AA and BA/AA ratios are unbalanced, promoting an environment that could be boosting the mechanisms underlying the pathogenesis of the disease. Since we have found statistical significant associations with the EDSS and the number of T2 lesions, but not with the number of relapses or gadolinium enhancing lesions, PA/AA and BA/AA ratios could be more associated with those mechanisms of the disease related to the neurodegenerative processes than those related with the activity of the disease.
This work was financially supported by Ministerio de Ciencia e Innovación (Proyectos de generación de conocimiento)-Fondo Europeo de Desarrollo Regional (Feder) (PID2021-126041OB-I00) and “Fundación LAIR”.
Article
Published version
English
Esclerosi múltiple; Inflamació; Àcids grassos; CHEMICALS AND DRUGS::Lipids::Fatty Acids::Fatty Acids, Volatile; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis; DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation; COMPUESTOS QUÍMICOS Y DROGAS::lípidos::ácidos grasos::ácidos grasos volátiles; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple; ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación
Wiley
Annals of Clinical and Translational Neurology;12(3)
https://doi.org/10.1002/acn3.52259
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PID2021-126041OB-I00
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - CEMCAT [136]
Articles científics - VHIR [1655]